You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤雙鶴(600062.SH):公司藥品新進國家醫保目錄
格隆匯 12-13 17:40

格隆匯12月13日丨華潤雙鶴(600062.SH)公佈,國家醫保局、人力資源社會保障部關於印發《國家基本醫療保險、工傷保險和生育保險藥品目錄(2023年)》的通知。根據該通知,華潤雙鶴藥業股份有限公司的產品拉考沙胺口服溶液通過競價納入《國家醫保目錄》,獨家代理產品八氟丙烷脂質微球注射液通過醫保談判納入《國家醫保目錄》。

2022年,公司拉考沙胺口服溶液銷售收入為人民幣7.5萬元,佔公司2022年度營業收入約0.001%;2023年前三季度,公司拉考沙胺口服溶液銷售收入為人民幣48.4萬元,佔公司2023年前三季度營業收入約0.01%。八氟丙烷脂質微球注射液目前尚未形成市場銷售。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account